Back

Use of emgliflozin in the prevention of cardotoxicity.The EMPACARD - PILOT TRIAL. 12 - months Follow -up

20 June 2025 (00:00 - 00:00)
Organised by: Logo
Congress Presentation Part of: Prevention of cancer therapy-related cardiovascular disease Stratification, Prevention and Monitoring CCO Premium Access ESC Cardio-Oncology 2025 Council of Cardio-Oncology

About the speaker

Photo
Doctor Andres Jose Daniele

Institute of Oncology Angel H. Roffo, Buenos Aires (Argentina)

5 More presentations in this session

Presentation thumbnail
Performance of a survival staging system incorporating sST2 in patients with light chain amyloidosis
Doctor D. Kim (Seoul, KR)
Abstract Slides Video
Presentation thumbnail
Effect of sacubitril/valsartan or enalapril on left ventricular function in patients with hematologic malignancies treated with bone marrow transplantation
Assistant Professor D. Farmakis (Athens, GR)
Abstract Slides Video
Presentation thumbnail
Safety and efficacy of S-1-based treatment in colorectal cancer patients who switched to S-1 after development of cardiotoxicity on fluoropyrimidine-based adjuvant or neoadjuvant treatment
Doctor S. Kinos (Tampere, FI)
Abstract Slides Video
Presentation thumbnail
Cardiomyocyte but not endothelial expression of PD-L1 is required to protect from Immune-Checkpoint-Inhibitor-Associated Myocarditis (ICIM)
Doctor M. Heckmann (Heidelberg, DE)
Abstract Slides Video
Presentation thumbnail
Quality indicators in cardio-oncology: a survey from the working group of cardiotoxicity and cardioprotection of the italian society of cardiology (SIC)
Associate Professor G. Novo (Palermo, IT)
Abstract Slides Video

Access the full session

Session thumbnail
Prevention of cancer therapy-related cardiovascular disease

The Event

Event poster

ESC Cardio-Oncology 2025

20 June - 21 June 2025

ESC 365 is supported by

novartis Explore sponsored resources

ESC 365 is supported by

novartis Explore sponsored resources